Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
CCR5, as the major co-receptor for HIV-1 entry, is an attractive novel target for the pharmaceutical industry in the HIV-1 therapeutic area. In this study, based on the structures of maraviroc and 1,4-bis(4-(7-chloroquinolin-4-yl)piperazin-1-yl)butane-1,4-dione (1), which was identified using struct...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2008-10-01
|
Series: | Molecules |
Subjects: | |
Online Access: | http://www.mdpi.com/1420-3049/13/10/2426/ |
id |
doaj-9a4aeb148883486eb442bc86f10df21f |
---|---|
record_format |
Article |
spelling |
doaj-9a4aeb148883486eb442bc86f10df21f2020-11-25T00:21:02ZengMDPI AGMolecules1420-30492008-10-01131024262441Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment AssemblyHualiang JiangJian LiXin XieYu ZhangJin ZhuKunqian YuEnkun ZhouYanqing LiuCCR5, as the major co-receptor for HIV-1 entry, is an attractive novel target for the pharmaceutical industry in the HIV-1 therapeutic area. In this study, based on the structures of maraviroc and 1,4-bis(4-(7-chloroquinolin-4-yl)piperazin-1-yl)butane-1,4-dione (1), which was identified using structure-based virtual screening in conjunction with a calcium mobilization assay, a series of novel small molecule CCR5 antagonists have been designed and synthesized through fragment assembly. Preliminary SARs were obtained, which are in good agreement with the molecular binding model and should prove helpful for future antagonist design. The novel scaffold presented here might also be useful in the development of maraviroc-derived second generation CCR5 antagonists.http://www.mdpi.com/1420-3049/13/10/2426/CCR5 antagonistfragment assemblyHIV-1molecular modeling |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hualiang Jiang Jian Li Xin Xie Yu Zhang Jin Zhu Kunqian Yu Enkun Zhou Yanqing Liu |
spellingShingle |
Hualiang Jiang Jian Li Xin Xie Yu Zhang Jin Zhu Kunqian Yu Enkun Zhou Yanqing Liu Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly Molecules CCR5 antagonist fragment assembly HIV-1 molecular modeling |
author_facet |
Hualiang Jiang Jian Li Xin Xie Yu Zhang Jin Zhu Kunqian Yu Enkun Zhou Yanqing Liu |
author_sort |
Hualiang Jiang |
title |
Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly |
title_short |
Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly |
title_full |
Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly |
title_fullStr |
Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly |
title_full_unstemmed |
Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly |
title_sort |
discovery of a novel ccr5 antagonist lead compound through fragment assembly |
publisher |
MDPI AG |
series |
Molecules |
issn |
1420-3049 |
publishDate |
2008-10-01 |
description |
CCR5, as the major co-receptor for HIV-1 entry, is an attractive novel target for the pharmaceutical industry in the HIV-1 therapeutic area. In this study, based on the structures of maraviroc and 1,4-bis(4-(7-chloroquinolin-4-yl)piperazin-1-yl)butane-1,4-dione (1), which was identified using structure-based virtual screening in conjunction with a calcium mobilization assay, a series of novel small molecule CCR5 antagonists have been designed and synthesized through fragment assembly. Preliminary SARs were obtained, which are in good agreement with the molecular binding model and should prove helpful for future antagonist design. The novel scaffold presented here might also be useful in the development of maraviroc-derived second generation CCR5 antagonists. |
topic |
CCR5 antagonist fragment assembly HIV-1 molecular modeling |
url |
http://www.mdpi.com/1420-3049/13/10/2426/ |
work_keys_str_mv |
AT hualiangjiang discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly AT jianli discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly AT xinxie discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly AT yuzhang discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly AT jinzhu discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly AT kunqianyu discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly AT enkunzhou discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly AT yanqingliu discoveryofanovelccr5antagonistleadcompoundthroughfragmentassembly |
_version_ |
1725364260766220288 |